Current treatments for depression are often seen as inadequate, either in terms of accessibility or effectiveness. But what could the next step be for treatment? Research published today in Pilot and Feasibility Studies evaluated what barriers could impact the use of behavioral activation programs for major depressive disorders and here, co-author Dr Zainab Samaan discusses what this might mean for future research and practice.
Monthly Archives: April 2016
Jan Foster writes here about the complicated maze of policy changes for the NHS, and asks the Director of Policy and Strategy at the NHS Providers about how they help to implement new policies and support their members.
In 2014, Harm Reduction Journal published an article that examined the legal compatibility of Mexico’s ‘ley de nacromenudeo‘ drug policy reform in the context of broader changes occurring within international drug policy. With a United Nations General Assembly Special Session (UNGASS) on the world drug problem set to take place in just a few days, co-author Timothy Mackey and Meredith Meacham explain why now is a crucial time to fundamentally rethink the future of global governance for drug policy.
The experts in the European Liver Patients Association (ELPA) Hep-CORE advisory group provide a window on the broad range of hepatitis activities and perspectives in Europe today. Hep-CORE PI Jeffrey Lazarus has been interviewing some of them about how they came to work with viral hepatitis, how the field has been changing, and what new research is called for.
The experts from the European Liver Patients Association (ELPA) Hep-CORE advisory group provide a great window on the diversity of hepatitis activity and perspectives in the region. In this series of short interviews, Hep-CORE PI Jeffrey Lazarus asked them how they came to work with viral hepatitis, how the field has been changing, and where new research is called for.
Jeffrey Lazarus talks here about the changes he has seen in the hepatitis field since the International Liver Congress in 2007.